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claudin-7, ezrin, MET, ß-catenin). Phenotypically, no mor-
phological changes of the actin cytoskeleton were seen.
Conclusions Upregulation of CITED4 in SW480 resulted 
in no obvious phenotype. CITED4 shRNA-mediated 
knockdown led to decreased cellular proliferation and mod-
ulation of a large number of genes, including the c-MET 
tyrosine kinase and several actin-associated adherens junc-
tions/tight junction genes.
Keywords Gene expression · Colorectal cancer · 
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Introduction
CITED4 (CREB-binding protein/P300-interacting trans-
activator with ED-rich tail, member 4) is one member of 
the CITED family of proteins known to participate in the 
regulatory activity of several genes, including TGFB, ER, 
TFAP2 and HIF1A. CITED1 (msg1), CITED2 (mrg1, 
p35srg) and CITED4 (mrg2) were originally identified as 
a family of homologous proteins possessing a conserved 
transactivating (CR2) domain that binds and transactivates 
the transcriptional regulator/histone acetyl transferase 
CBP/P300. A mouse transcript for CITED4 was originally 
identified, shown to be expressed in a wide variety of tis-
sues, and to bind CBP/P300 (Yahata et al. 2002). Braganca 
et al. (2002) successfully identified human CITED4 tran-
scripts, demonstrated its expression in a large number of 
human organs and showed that the carboxyterminal end 
of the resulting protein interacts with the CH1 domain 
of HIF-1alpha and, similar to CITED2 (Bamforth et al. 
2001), also interacted with all known human isoforms of 
the transcription factor AP2 (TFAP2). CITED4 was shown 
Abstract 
Purpose CITED4 is one member of a family of tran-
scriptional cofactors, several of which are deregulated in a 
variety of tumors, including colorectal cancer (CRC). We 
modulated CITED4 expression, in vitro, and analyzed the 
associated phenotypic and gene expression changes.
Methods CITED4-overexpressing and shRNA-mediated 
knockdown cell lines and control cell lines were established 
in the CRC cell line SW480. The cells were analyzed for 
changes in proliferation, apoptosis/cell cycle, migration, 
invasion, colony formation and adhesion. mRNA expres-
sion changes were determined by microarray and pathway 
analysis, and several deregulated genes were validated by 
qRT-PCR and Western blotting. Based on results obtained 
from these studies, the status of the actin cytoskeleton was 
evaluated by phalloidin/vinculin staining.
Results Phenotypically, the CITED4-overexpressing cell 
line showed only moderate changes in adhesion. Microar-
ray analysis identified several deregulated genes, including 
several G protein-coupled receptors. Phenotypic analysis 
of the CITED4 shRNA knockdown cell line demonstrated 
decreased cell proliferation and G2 cell cycle blockage. 
Microarray analysis identified many deregulated genes, 
and pathway analysis discovered genes linked to actin-
associated adherens junctions/tight junctions (claudin-4, 
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to negatively regulate the binding of HIF-1alpha to CBP/
P300, thus inhibiting hypoxia-activated transcription (Fox 
et al. 2004). Several members of the CITED gene family 
as well as CBP/P300 have been implicated in carcinogen-
esis. Analysis of CITED4 in a large series of human breast 
tumors by immunohistochemistry showed both cytoplas-
mic and nuclear staining, the nuclear staining of CITED4 
negatively correlating with HIF-1alpha expression, tumor 
size and tumor grade (Fox et al. 2004). In a further study, 
Tews et al. analyzed tumor material from patients with oli-
godendral brain tumors exhibiting a loss of chromosomes 
1p 19q. Comparison of gene expression in these patients 
with tumors not possessing the 1p/19q deletions showed 
downregulation of CITED4 expression (Tews et al. 2006). 
In a further patient study, DNA methylation and mutation 
analysis of patients possessing the 1p 19q deletions showed 
that the CITED4 promoter regions of patients harboring the 
deletions were often methylated, and this methylation was 
associated with longer overall/progression-free survival 
(Tews et al. 2007). No mutations in CITED4 were observed 
either in this study or in one further analysis of glioblas-
toma patients (Tews et al. 2007; Torres-Martin et al. 2008). 
In breast cancer patients, no mutations and only infrequent 
hypermethylation was observed (Huang et al. 2011).
Our previous efforts at CITED4 analysis in oligodendral 
brain tumors (Tews et al. 2006, 2007) coupled with previ-
ous publications describing a role for another member of 
the CITED family (CITED2) in colorectal (CRC) cancer 
invasion (Bai and Merchant 2007), led to this current study 
which deregulates and analyzes CITED4 activity in a colo-
rectal cancer cell line.
Methods
Cell culture
SW480 and HEK293T cells were obtained from the Ger-
man Collection of Microorganisms and Cell Cultures 
(DSMZ). Cultures were grown in RPMI-1640 medium 
(Sigma) containing 10 % fetal bovine serum (FBS) (Bio-
chrom) and 100 u penicillin/100 µg streptomycin (Sigma). 
All cell lines were passaged every 3–4 days. The cell lines 
in this study were regularly tested for contamination and 
authenticity.
CITED4 overexpression and knockdown vectors
For the overexpression construct, the open reading frame 
of human CITED4 (nm_133467, 220–774 bp) was ampli-
fied by PCR and then cloned into the pCDNA4 HISMAX 
vector (pCNDA4 HISMAX TOPO TA Expression Kit, Inv-
itrogen). Thereafter, a green fluorescent protein (GFP gene 
containing an internal ribosomal entry site (IRES-GFP), 
a kind gift of Dr. Daniel E. Stange, Dresden, Germany) 
was cloned into the EcoRI-XhoI site of the CITED4 con-
struct as well as into the empty vector, and both constructs 
(IRES-GFP and CITED4-IRES-GFP) were sequenced. 
For the knockdown experiments, five short hairpin (sh) 
RNA constructs to CITED4, as well as a control hairpin, 
GFP and empty (pLKO.1) vector were obtained from the 
human RNAi Consortium library (Sigma-Aldrich) (Mof-
fat et al. 2006). Four of the five CITED4 shRNA con-
structs showed significant knockdown in SW480 cells 
following transient transfection and qRT-PCR. Two of 
the shRNAs TRCN0000020921 (CCGGCGCCGAACT-
C AT C G AC G AG G AC T C G AG T C C T C G T C G AT-
GAGTTCGGCGTTTTT) (ND1) and TRCN0000020923 
(CCGGCGGCATGGACGCCGAACTCATCTCGAGAT-
GAGTTCGGCGTCCATGCCGTTTTT) (ND2) were used 
for the creation of two permanent cell lines. The second 
shRNA-containing cell line (TRCN0000020293) (ND2) 
was used for complete phenotypic characterization and 
microarray analysis.
Lentivirus preparation
Replication-incompetent lentivirus (CITED4 shRNA, 
control shRNA or empty vector) was created using a sec-
ond-generation lentiviral packaging system. The CITED4 
shRNA/control plasmid constructs (7 µg) were co-trans-
fected together with the helper plasmids pMD2.G (2.1 µg) 
and PSPAX2 (5.7 µg) into 2 × 106 HEK293T cells/10 cm 
plate using Trans-IT-L1 transfection reagent according 
to the manufacturer’s instructions (Mirius, Madison, WI). 
The medium was changed after the first day, and the virus-
containing medium was harvested 2 days later. The virus 
particles were concentrated by ultracentrifugation (SW41 
rotor, 25,000 RPM, 1.5 h) in a Beckman L70 ultracentri-
fuge (Beckman-Coulter, Krefeld, Germany) and taken up 
in 100 µl PBS. The lentiviral titer was determined by GFP 
transduction in HEK293T cells as well as by puromycin-
selected limited dilution and colony formation.
Preparation of permanent cell lines
The CITED4-overexpressing cell line and control cell line 
were prepared by transfection of SW480 with the IRES-
GFP and CITED4-IRES-GFP constructs using Jetprime 
transfection reagent (PeqLab, Erlangen, Germany) accord-
ing to the manufacturer’s recommendations. Selection was 
performed starting at day 3 using 300 µg/ml zeocin (Inv-
itrogen/Life Technologies, Darmstadt, Germany). For the 
creation of CITED4 shRNA permanent cell line/control 
cell lines, SW480 cells were transduced with a tenfold mul-
tiplicity of infection (MOI) of the respective lentivirus (see 
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above). The virus was removed by medium change at day 
1, and selection was performed starting at day 3 using 2 µg/
ml puromycin.
Proliferation and colony formation assays
Proliferation of both the CITED4-overexpressing/shRNA 
cell line was analyzed. To this end, 5 × 104 cells of each 
cell line were plated in triplicate into 12-well plates and 
grown for a period of 8 days. The wells were harvested at 
day 2, 4, 6 and 8 and the cells counted using a Vi-Cell XR 
cell counter (Beckman-Coulter, Krefeld, Germany). For 
colony formation assays, 1 × 103 cells of each respective 
cell line were plated in triplicate into six-well plates using 
2 ml medium/well. The medium was changed every 3 days. 
After 17 days, the medium was removed, and the cells 
were washed in PBS and stained 7 min with 2 % meth-
ylene blue/50 % ethanol. Thereafter, the excess stain was 
removed by H2O washings. The colonies (>50 cells) were 
manually quantified using the ImageJ program.
Further phenotypic assays
(Migration, invasion, cell cycle analysis, adhesion array 
assay, See Supplementary Methods).
Microarray analysis
For microarray analysis of both the SW480 CITED4-
overexpressing cell line (CITED4-ires-GFP)/control cell 
line (ires-GFP) and the CITED4 shRNA permanent cell 
line/control cell lines, 1 × 105 cells from each line were 
passaged into 12-well plates containing 1 ml RPMI-1640 
plus 10 % FCS and penicillin/streptomycin. The cells were 
harvested at day 1, 3 and 5 for total RNA preparation (see 
qRT-PCR analysis). Several separate experiments were 
performed, and equal amounts of total RNA from each 
specific time points for each cell line were pooled. RNA 
integrity (RIN > 8.5) was confirmed using an Agilent Bio-
analyzer. Microarray hybridization of each of the samples 
was performed on Agilent 4 × 44 k arrays according to the 
manufacturer’s instructions using a two-color system with 
Universal Human Reference RNA (Agilent, Santa Clara, 
CA) as a control for each sample. The hybridized micro-
arrays were scanned using an Agilent Microarray Scan-
ner (GS2565CA), and raw data were generated from the 
scanned images using Agilent Feature Extraction Software. 
Further processing and normalization (filter vsn) were 
performed using Chipyard, an in-house developed micro-
array analysis tool. Venn analysis was performed using 
the Chipster Microarray Analysis Program (Kallio et al. 
2011). Microarray data are available in the ArrayExpress 
database (www.ebi.ac.uk/arrayexpress) under the acces-
sion numbers E-MTAB-2486 and E-MTAB-2487.
R2 analysis and functional gene annotation
Expression analysis of CITED4 using the data of Jorissen 
et al. (2009) was evaluated using the R2 microarray analy-
sis and visualization platform (http://r2.amc.nl). Functional 
annotation of the expression data from the microarray anal-
ysis obtained in the current study was performed using the 
DAVID bioinformatics resource (Huang et al. 2009a, b). 
The DAVID Functional Gene Classification Tool allowed 
the classification of the deregulated genes into functional 
groups using key terms associated with each group. In 
addition, KEGG database analysis grouped relevant genes 
into specific biochemical pathways. The gene lists gener-
ated from these groups were used to identify candidates for 
further evaluation.
Microarray candidate gene validation by qRT‑PCR
All qRT-PCR experiments were analyzed in accord-
ance with the MIQE guidelines (Bustin et al. 2009). For 
each sample, 2.2 × 106 of each cell line was plated into 
10 cm plates in RPMI-1640 plus 10 % FCS and penicil-
lin/streptomycin and grown for 1, 3 or 5 days. The cells 
were then harvested for total RNA preparation using the 
RNEasy kit (Qiagen, Hilden, Germany). Genomic DNA 
removal and first-strand synthesis (1 µg total RNA) were 
performed using the Quantitect Reverse Transcription Kit 
(Qiagen, Hilden, Germany) according to the manufac-
turer’s instructions. The 20 µl first-strand syntheses were 
diluted 1/3 in water and 2 µl was used for quantitative 
real-time PCR together with 10 pmol of the appropriate 
primer pairs (see Supplementary Table 1) and 6 µl Abso-
lute SYBR Green Rox Mix (Thermo Scientific, Schwerte, 
Germany). The reaction mixtures were amplified/quantified 
using the 7900HT Real-Time PCR System thermocycler 
(Life Technologies, Darmstadt, Germany) using the fol-
lowing cycling conditions 50 °C—2 min, 95 °C—15 min, 
40 cycles of 95 °C—15 s, 60 °C—1 min for amplification 
followed by 95 °C—15 s, 60 °C—15 s for annealing curve 
determination. Standard curves were performed for each of 
the amplifications. The genes of interest were normalized 
against the housekeeping genes DCTN2 and PGK1.
Western blot analysis
Cell were harvested, pelleted and resuspended in 3× 
amount of RIPA buffer (50 mM Tris/HCL pH7.4, 150 mM 
NaCl, 1 % Triton X100, 0.5 % deoxycholate, 0.1 % SDS) 
with protease inhibitors (Complete Mini, Roche), incubated 
on ice for 45 min and pelleted thereafter by centrifugation. 
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The supernatant was quantitated using BCA protein detec-
tion reagent (Pierce, Rockford, IL). Twenty micrograms of 
the protein lysate was separated on 4–12 % polyacrylamide 
gels (Nupage-Novex, Invitrogen/Life Technologies, Darm-
stadt, Germany) using 1× MES-SDS as a running buffer. 
The separated proteins were transferred electrophoretically 
(2 h at 240 mAmp) onto a PVDF membrane (Millipore, 
Billerica, MA) using an XCELLII transfer module (Inv-
itrogen) in transfer buffer (48 mM Tris, 39 mM glycine, 
20 % methanol). Following the protein transfer, the blots 
were incubated in blocking buffer [5 % milk powder in 
TBS (50 mM Tris pH7.4, 150 mM NaCl)] for 1 h. Thereaf-
ter, the blot was incubated with the primary antibody at the 
appropriate dilution (see Supplementary Table 2) in block-
ing buffer for 1 h or overnight. Then, the antibody was 
removed and the blot washed 3 × 10 min in TBST (TBS 
with 0.02 % Tween 20). Thereafter, the blot was incubated 
with the secondary antibody at the appropriate concentra-
tion (see Supplementary Table 2) in blocking buffer for 1 h. 
After three further washes in TBST, the protein of interest 
was identified using enhanced chemiluminescence (ECL, 
Pierce) coupled with X-ray film exposure.
Actin/Focal adhesion assay
2 × 105 cells of the CITED4 knockdown cell lines and 
the respective controls were passaged onto sterile Labtek 
Chamber slides (Brand, Wertheim, Germany) in 1 ml 
RPMI-1640 plus 10 % FCS and penicillin/streptomycin. 
The slides were prepared for fluorescence microscopy of 
actin (phalloidin-TRIC staining) and vinculin (Alexa 488 
staining) using an actin and focal adhesion staining kit 
(Millipore) according to the manufacturer’s instructions. 
The dilutions of phalloidin-TRIC, vinculin primary anti-
body and the secondary antibody can be found in Supple-
mentary Table 2.
Statistical analysis
Statistical evaluation of the phenotypic data/qRT-PCR 
assays were demonstrated by calculation of standard devi-
ation for small samples (n − 1) or two-tailed Student’s t 
tests on 2–3 separate experiments with a total sample size 
of 6–9. The exact number of experiments and sample size 
are shown in the figure legends.
Results
The R2 database, a collection of previously published 
high-content molecular studies (R2: microarray analysis 
and visualization platform-http://r2.amc.nl), was screened 
for data of CITED4 in CRC. Microarray expression data 
from 226 patients exhibiting different stages of CRC (Joris-
sen et al. 2009) were evaluated through the R2 database by 
Kaplan–Meier analysis. Fourteen percent of the patients in 
the study exhibited a high CITED4 expression level which 
was associated with a tendency toward poorer relapse-free 
survival (Supplementary Fig. 1).
In order to analyze the effects of CITED4, in vitro, the 
CRC cell line SW480, derived initially from a 50-year-
old male with Dukes stage B CRC (Leibovitz et al. 1976), 
was used to generate both a CITED4-overexpressing and 
two CITED4 shRNA-mediated knockdown permanent 
cell lines. qRT-PCR (Fig. 1a–c) and Western blot analysis 
(ND2, Fig. 1d) of both cell lines showed a strong upregu-
lation of CITED4 (ca. 20 fold by qRT-PCR—Fig. 1a) for 
the overexpressing cell line and a strong downregulation 
(ca 80–90 %) in the two shRNA knockdown cell lines 
(Fig. 1b, c). Western blot analysis of the CITED4-over-
expressing cell line showed a strong increase in CITED4 
protein production (Fig. 1d, left side). Similar analysis in 
the ND2 CITED4 knockdown cell line showed the com-
plete ablation of protein production (Fig. 1d, right side; 
Note: The following experiments were performed with 
the ND2 knockdown cell line due to its better degree of 
downregulation). The phenotype of both the overexpress-
ing and the second shRNA knockdown cell lines were 
evaluated by proliferation studies, cell cycle analyses, clo-
nogenicity assays, migration (scratch), invasion assays as 
well as adhesiveness to several basement membrane pro-
teins. While the CITED4-overexpressing cell line showed 
no difference in proliferation when compared to the con-
trol cell line (Fig. 2a), both of the CITED4 shRNA knock-
down cell lines (ND1 and ND2) showed a decrease in cell 
proliferation (Fig. 2b, c), and the second cell line showed 
a much stronger decrease in proliferation (ca. 40 %) dur-
ing the linear growth phase when compared to the empty 
vector and control shRNA cell lines (Fig. 2b). Therefore, 
the ND2 CITED4 shRNA knockdown cell line was used 
for all further analyses. Cell cycle analysis of the CITED4 
shRNA knockdown cell line at day 4 after plating (Fig. 2d) 
showed no change in the subG1 fraction of the cell cycle 
when compared to the empty and control vectors, indicat-
ing that the inhibition of proliferation was not associated 
with apoptosis. Additional assessment of apoptosis was 
also evaluated in these cells lines by FACS analysis of 
annexin V/7-AAD stainings, but these experiments showed 
no changes in annexin V levels or cell viability when com-
pared to controls (data not shown). The cell cycle analyses 
did show, however, a moderate increase in the G2 fraction 
when compared to the control cell lines, indicating that the 
inhibition of proliferation was associated with a moderate 
G2 blockage of the cell cycle (Fig. 2d).
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Clonogenicity studies of both the CITED4-overex-
pressing and CITED4 shRNA permanent cell line showed 
no changes in proliferative capacity between the CITED4 
deregulated cell lines when compared to the respective con-
trol lines (Supplementary Fig. 2A–C).
Migration (scratch) assays of both the overexpress-
ing and knockdown cell line were analyzed at 0, 6, 12, 
24 and 30 h after scratching (only the 30 h analysis is 
shown, Supplementary Fig. 3). No change in migra-
tory activity was seen between the overexpression/and 
shRNA knockdown cell lines when compared to the 
control cell lines. Cellular invasion was also analyzed 
in the CITED4-overexpressing/shRNA knockdown 
cell lines using Matrigel-coated Transwell chambers at 
48 h after plating (Supplementary Fig. 4). No increase 
in invasiveness was seen in the CITED4-overexpressing 
cell line (supplementary Fig. 4A), and a tendency toward 
increased invasiveness seen in the CITED4 shRNA per-
manent cell line was not statistically significant (Supple-
mentary Fig. 4B).
Analysis of adhesiveness to several known basement 
membrane proteins using a commercially available adhe-
sion array system demonstrated an increased adhesiveness 
of the CITED4-overexpressing cell line to collagen IV and 
vitronectin when compared to the control cell line (Supple-
mentary Fig. 5A). In contrast, no changes in adhesiveness 
to any of the basement membrane proteins were seen in the 
CITED4 shRNA knockdown cell line compared to controls 
(Supplementary Fig. 5B).
Expression analysis was performed in the CITED4-
overexpressing, as well as the CITED4 shRNA knockdown 
cell lines, at day 1, 3 and 5 after plating using Agilent 
4 × 44 K microarrays. Upon comparison of the overex-
pressing cell line with the control line, very few genes 
(120) were deregulated over the 5-day period, despite 
using a log2 fold change of one as a cutoff for deregula-
tion (see Supplementary Table 3). In contrast, analysis of 
the CITED4 shRNA permanent cell line compared to the 
empty vector/control shRNA cell lines showed a larger 
number of deregulated genes (551 CITED4 shRNA/empty 
vector; 306 CITED4 shRNA/control shRNA) (Fig. 3a–c, 
Supplementary Table 4), 214 of which were present in both 
datasets. Using the significantly deregulated datasets from 
the CITED4-overexpressing/knockdown cell lines, func-
tional annotation analysis was performed using the DAVID 
bioinformatics resource. In the CITED4-overexpressing 
cell line dataset, no obvious pathways were discerned from 
the data. However, manual annotation and literature search 
demonstrated that, in addition to SYK kinase, three G pro-
tein-coupled receptors were deregulated (LGR6, GPR64, 
GPR110), two of which are, by homology, adhesion-asso-
ciated G protein-coupled receptors. The DAVID database 
identified two putative annotation clusters in the CITED4 
shRNA permanent cell line (actin, epithelial/epidermal 
differentiation, see Fig. 3d). Functional analysis using 
the Kyoto Encyclopedia of Genes and Genomes (KEGG) 
pathway database integrated into the DAVID program 
identified four functionally annotated cellular processes, 
Fig. 1  Validation of CITED4 
expression in the SW480 
CITED4-overexpressing/
shRNA-mediated knockdown 
permanent cell lines a–c qRT-
PCR analysis of the respec-
tive cell line at day 3 (three 
experiments, n = 6). a CITED4-
overexpressing cell line. b First 
CITED4 shRNA permanent cell 
line. c Second CITED4 shRNA 
permanent cell line. d Western 
blot analysis of the CITED4-
overexpressing permanent and 
control cell line (left); second 
CITED4 shRNA permanent cell 
line and controls (right). *, t test
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namely leukocyte transendoethelial migration, adherens 
junctions, colorectal cancer and tight junctions. Many of 
the genes described in these pathways overlapped with 
each other (Fig. 3d).
In order to validate our CITED4-overexpressing/knock-
down microarray data, we performed time courses for 
quantitative real-time PCR (qRT-PCR) analysis on several 
genes derived from either the manual search of the over-
expressing cell line or, for the knockdown cell line, the 
KEGG pathway genes list using RNA derived from mul-
tiple time course experiments. Although nearly all of the 
genes analyzed showed a tendency to correlate with the 
microarray data in general, only ca. 50 % of the genes ana-
lyzed showed a statistically significant deregulation, and 
a great majority were deregulated at more than one time 
point. Figure 4a, b shows the day 5 values of the signifi-
cantly deregulated genes. Three of the 13 genes shown to 
be significantly deregulated by qRT-PCR were also vali-
dated at the protein level by Western blot analysis (Fig. 5).
In order to see if the knockdown of CITED4 in the 
shRNA permanent cell line induced obvious morphologi-
cal cell changes in either the actin cytoskeleton or in focal 
adhesion contact points, the CITED4 shRNA permanent 
cell line and controls were stained with phalloidin (F-actin) 
and vinculin (focal adhesions) 3 days after cell line plat-
ing (Supplementary Fig. 6). No obvious changes in either 
the actin filament cytoskeleton or in focal adhesion contact 
points were seen at this time point.
Downregulation of c-MET might be causal for the inhi-
bition of proliferation seen in the CITED4 shRNA per-
manent cell line. As such, transient transfections of the 
CITED4 shRNA permanent cell lines were performed 
using a c-MET overexpression construct in order to res-
cue the phenotype. Overexpression of c-MET resulted in a 
strong increase in c-MET mRNA and protein expression in 
the CITED4 shRNA permanent cell line as well as in the 
control cell lines, but the c-MET overexpression was not 
accompanied by increased proliferation in any of the cell 
lines (data not shown).
The effect seen in the SW480 CITED4 shRNA perma-
nent cell line (ND2) encouraged us to create two further 
CRC permanent cell lines by transduction of the same 
shRNA into LS174T and CL34 cells. Both permanent cell 
lines exhibited an effective knockdown of CITED4 mRNA. 
While no inhibition of proliferation was seen in LS174T, 
the inhibition of proliferation in CL34 was significant. 
However, as this effect was minor, we decided not to con-
tinue evaluation of these cell lines.
Fig. 2  Proliferation and cell cycle analyses of the CITED4-overex-
pressing/shRNA permanent cell lines. a–c Time course of prolifera-
tion for the respective cell lines (two experiments, n = 6). a Prolif-
eration assay—CITED4-overexpressing cell line and control. b, c 
Proliferation assay—first (ND1) and second (ND2) CITED4 shRNA 
permanent cell lines. d Quantitation of the histograms (two experi-
ments, n = 6). *t test, empty vector versus CITED4; **t test control 
shRNA versus CITED4
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Discussion
Overexpression of CITED4 results in no significant 
changes in proliferation or colony formation, but shows a 
moderate upregulation of adhesiveness to the basement 
membrane proteins collagen IV and vitronectin, which, 
however, is not associated with a change in invasive phe-
notype. Decreased collagen IV expression is seen in CRC 
patients and is associated with poor prognosis (Havenith 
et al. 1988; Zeng et al. 1999). Vitronectin is absent in the 
normal colon, but appears to be expressed in CRC, pos-
sibly by induction of the surrounding fibroblasts by the 
tumor cells (Tomasini-Johansson et al. 1994). CITED4 
overexpression modulates expression changes in a small 
number of genes including three G protein-coupled recep-
tors, GPR64, GPR110 and LGR6. GPR64 and GPR110 
are assumed to be adhesion-associated G protein-coupled 
receptors based on the similarity of their extracellular 
domains to adhesion molecule-binding domains (Bjar-
nadottir et al. 2004, 2007). In the epididymis, GPR64 
co-localizes with actin and ezrin, which were also identi-
fied in the CITED4 shRNA knockdown microarray stud-
ies (see below). GPR110 has been shown to be overex-
pressed in lung and prostate cancer (Lum et al. 2010) and 
is upregulated in the CITED4-overexpressing cell line. 
LGR6, a stem cell-associated G protein-coupled receptor 
Fig. 3  Venn diagram of the CITED4 shRNA permanent cell line 
microarray data and DAVID pathway analyses. a CITED4 shRNA/
empty vector, day 1, 3, 5. b CITED4 shRNA/control shRNAs, day 1, 
3, 5. c Total CITED4 shRNA/empty vector versus CITED4 shRNA/
control shRNA. d Results of the DAVID pathway analysis
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modulated by the R-spondin family of ligands (Gong et al. 
2012), exhibits mutations and hypermethylation in a subset 
of analyzed CRC patients (Sjoblom et al. 2006; Schuebel 
et al. 2007). One further gene of interest is the SYK tyros-
ine kinase. Although primarily studied in lymphoid cells, 
numerous solid cancers have been shown to exhibit SYK 
deregulation, and SYK has been implicated as a putative 
tumor suppressor gene (Coopman and Mueller 2006). SYK 
overexpression in CRC cell lines leads to decreased prolif-
eration and invasiveness and appears to be hypermethylated 
in a subset of CRCs (Yang et al. 2013).
Downregulation of CITED4 results in a decrease in cell 
proliferation in the SW480 cell line coupled with a moder-
ate blockage in G2 of the cell cycle. No changes in apopto-
sis [cell cycle subG1 fraction or annexin V/7-AAD analysis 
(data not shown)], colony formation, migration, invasion 
or adhesion were noted. Dowregulation of CITED4 in two 
further CRC cell lines showed significant, but only minor, 
inhibition of cell proliferation in one of the lines. This is 
best explained by the inhibition of proliferation seen in the 
CITED4 knockdown being dependent upon the genetic 
background in which it occurs.
Fig. 4  qRT-PCR validation of 
a subset of deregulated genes 
identified from CITED4-over-
expressing/shRNA knockdown 
permanent cell line microarray 
analysis. Analyses performed 
at day 5 after plating (three 
experiments, n = 6). a CITED4-
overexpressing cell line/empty 
vector cell line, b CITED4 
shRNA permanent cell line, 1 
CITED4 shRNA cell line/empty 
vector cell line, 2 CITED4 
shRNA cell line/control shRNA 
cell line
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Knockdown of CITED4 in SW480 cells resulted in the 
deregulation of a large number of genes, several of which 
encode proteins seen together with actin-associated adhe-
rens/tight junctions (claudin-4, claudin-7, ß-catenin, ezrin) 
and/or cell proliferation (ß-catenin, MET). In the CITED4 
knockdown cell line, downregulation of MET was ini-
tially thought to be causal for the inhibition of proliferation 
seen upon knockdown, for MET and its ligand, hepatocyte 
growth factor/scatter factor (HGF/SF) is known to influence 
proliferation in a number of different cell types (Birch-
meier et al. 2003; Jiang et al. 1999). In addition, two mon-
oclonal antibodies generated against MET inhibited CRC 
tumor growth in a mouse xenograft model (van der Horst 
et al. 2009). However, in the current study, overexpression 
of c-MET did not lead to an increase in proliferation in 
the CITED4 shRNA permanent cell line or in SW480, in 
general (data not shown). C-MET is interesting for several 
further reasons. c-MET overexpression has been shown 
Fig. 5  Western blot valida-
tion for a subset of deregu-
lated genes derived from the 
CITED4-overexpressing/shRNA 
knockdown cell line microarray 
analyses. a SYK, b GPR110, 
c claudin-7 (CLDN7), d ezrin 
(EZR). GAPDH was measured 
as an internal standard
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to be a prognostic marker in CRC, summarized recently 
in two clinical study meta-analyses (Gao et al. 2015; Liu 
et al. 2015 and the references therein). A complex of MET, 
CD44 variant 6 and the MET ligand HGF has been identi-
fied in the colorectal cancer cell line HT-29 and has been 
demonstrated as being essential for MET activation (Orian-
Rousseau et al. 2002). The carboxyterminal portion of 
CD44 variant 6, which contains a binding region for the 
actin-associated protein ezrin, was also determined as being 
necessary for activation. Furthermore, claudin-7, CD44 
variant 6, EpCAM and the tetraspanin CP-029 appear to 
be upregulated in colorectal cancer with liver metastasis 
and form a common complex in regions termed tetraspa-
nin-enriched membrane microdomains (TEM) (Kuhn et al. 
2007). Most recently, EpCAM, CD44 and MET have also 
been identified in circulating tumor cells (CTCs) of breast 
cancer patients exhibiting metastasis (Baccelli et al. 2013). 
Therefore, in the current study, MET could also be a mem-
ber of a somewhat larger complex, and this complex might 
be, at least partially, regulated by CITED4. MET is also 
activated by HIF-1alpha, one of the known binding partners 
of CITED4 (Pennacchietti et al. 2003). However, CITED4 
(as well as CITED2) have been shown to bind and inac-
tivate HIF-1alpha, and in breast tumors, a negative cor-
relation exists between CITED4 and HIF-1alpha protein 
expression (Huang et al. 2011; Fox et al. 2004; Bhattacha-
rya et al. 1999; Freedman et al. 2003), which would appar-
ently contradict a role for HIF-alpha regulation of c-MET 
in the current study.
Downregulation of CITED4 modulates the transcription 
of several proteins associated with adherens/tight junctions 
(ezrin, claudin 4, claudin 7, ß-catenin, MET) in SW480 
cells. Ezrin, a known cytoskeletal linker which binds both 
to actin filaments and CD44 (Bretscher et al. 2002), is nec-
essary for the maintenance of intestinal villus apical polar-
ity (Saotome et al. 2004), has been shown to be a prognos-
tic marker in a larger clinical study (Patara et al. 2011) and 
has been implicated, together with CD44, in metastasis 
(Martin et al. 2003). Claudins are a large group of mem-
branous proteins essential for the formation of tight junc-
tions, multi-protein membrane-associated cellular struc-
tures responsible for the maintenance of epithelial cell 
polarity through isolation and division of the apical and 
basolateral regions by these structures. Claudin-4 and clau-
din-7 are known to be important for this polarity. In addi-
tion, several claudins also regulate the pericellular passage 
of small molecules and ions from the epithelial lumen to 
the underlying tissues (Hartsock and Nelson 2008; Turksen 
and Troy 2011). In mice, ablation of claudin-7 results in 
death due to barrier loss with resulting dehydration (Tatum 
et al. 2010). Analysis of claudins in several different 
tumor entities shows, with perhaps the exception of clau-
din 1, no clear-cut pattern between claudin expression and 
tumorigenicity. Claudin-4 has been shown to be strongly 
deregulated in gastric cancer (Reviewed in, Turksen and 
Troy 2011). In CRC, Ueda et al. (2007) showed that pri-
mary tumors exhibited similar claudin-4 expression as nor-
mal tissue, but invasiveness was associated with decreased 
claudin-4 expression. In contrast, Mees et al. (2009) saw 
increased claudin-4 expression in patients with ulcerative 
colitis-associated CRC. In colorectal cancer, the correlation 
between claudin-7 expression and metastasis is also not 
clear. Initially, two studies found that both primary CRC, as 
well as metastases, showed overexpression of claudin-7, the 
metastases in one study showing somewhat lower expres-
sion compared to the primary tumor (Darido et al. 2008; 
Kuhn et al. 2007). Kuhn et al. (2007), a clinical study of 
102 primary tumors and 66 metastases, also demonstrated 
co-localization of claudin-7 together with the membrane 
proteins EpCAM, CD44v6 and the tetraspanin CP-029 and 
found that this complex is associated with poorer disease-
free survival. In contrast, tumor-associated claudin-7 was 
either unchanged or decreased in invasive areas in three 
further CRC studies (Nakayama et al. 2008; Oshima et al. 
2008; Bornholdt et al. 2011).
CITED4 is one of the three members of the CITED fam-
ily in humans (CITED1, CITED2, CITED4). The CITED 
family members show not only fairly high sequence con-
servation, but also show similar binding partners, such as 
HIF-1alpha, CBP/P300 and TFAP2. All three members 
of the CITED4 family have been shown to be involved, 
to some degree, in tumorigenesis (Meniel et al. 2013; 
Nasu et al. 2013; Huang et al. 2011; Fox et al. 2004; Tews 
et al. 2007; Bai and Merchant 2007). In colorectal cancer, 
CITED1 is overexpressed in human and mouse (APCmin/+ 
mouse model) colorectal tumors. Knockdown of CITED1 
in the APCmin/+ mouse model is associated with increased 
survival accompanied by a paradoxical WNT-associated 
increase in apoptosis (Meniel et al. 2013; Nasu et al. 2013). 
Currently, no clinical studies of CITED2 in CRC are avail-
able, although CITED2 protein expression is increased in 
ulcerative colitis, a condition often associated with CRC 
(Yoshida et al. 2011). shRNA-mediated downregulation of 
CITED2 in the CRC cell line RKO resulted in a cell mor-
phology change which, by phalloidin staining, was shown 
to affect the actin cytoskeleton, and this knockdown of 
CITED2 resulted in increased cellular invasiveness in a 
Matrigel invasion assay (Bai and Merchant 2007). In addi-
tion, microarray analysis was performed in this study, and 
although the microarray data were not directly presented, 
the authors identified an increased expression of matrix 
metalloproteinase-13 (MMP-13), which would tend to 
support the invasion assay data. As such, this data pointed 
to a role of CITED2 in CRC invasiveness. In the current 
study, expression microarray analysis followed by path-
way analysis also identified several genes (claudin-7, ezrin, 
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ß-catenin, c-MET) which are known to bind/associate with 
the actin cytoskeleton. However, neither Matrigel invasion 
assays nor phalloidin (F-actin) staining was associated 
with changes in invasiveness or actin cytoskeleton upon 
knockdown of CITED4, in contrast to what was seen in the 
CITED2 study. The CITED4 shRNA-mediated knockdown 
did, however, result in an inhibition of cellular prolifera-
tion, which was not seen in the CITED2 study.
Conclusions
Increased expression of CITED4 in SW480 cells did not 
lead to an obvious cellular phenotype, but did result in 
the expression of several (adhesion) associated G protein-
coupled receptors. Knockdown of CITED4 in the same cell 
line inhibited cellular proliferation accompanied by a mod-
erate (G2) cell cycle blockage. Expression analysis showed 
the deregulation of a large number of genes, including 
genes involved in the formation of actin-associated adher-
ens/tight junctions, however, without an obvious disruption 
of the actin cytoskeleton.
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